Mahesh V. Patel, Chief Executive Officer at Lipocine Inc. (LPCN), bought 25,000 shares at $2.02 ($51K) on 2026-04-02, disclosed to the SEC on 2026-04-02.
CEO Mahesh V. Patel executed the largest purchase of his career, buying 25,000 shares at $2.02, signaling confidence despite recent stock weakness. This move comes as the shares have plummeted over 74% over the last 90 days, potentially offering a contrarian entry point.
The stock is trading near its 52-week low of $1.81, having fallen 74.38% over the last 90 days and 83.43% from its 52-week high of $12.37. Despite this steep decline, the current price of $2.05 remains 13.26% above the 52-week low.
Q1 earnings are scheduled for May 7, 2026, following a recent report where the company beat revenue estimates despite a loss. Additionally, Lipocine expects to submit a New Drug Application for LPCN 1154 in mid-2026 based on Phase III trial data.
The company is currently unprofitable, with a forward P/E of -1.84 and recent reports showing a loss of 34 cents per share. With a short interest of 2.21% of the float, there is potential for short covering or continued bearish sentiment if the company fails to meet its mid-2026 NDA submission timeline.
Clearly above the average filing.
| Filing → |
| LPCN | BUY | 2023-03-24 | $48K | — | Filing → |
| LPCN | BUY | 2023-03-17 | $17K | — | Filing → |
| LPCN | BUY | 2022-11-14 | $29K | — | Filing → |